A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Cited by (1,036)

Items 101–200 of 1,036

1. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design
   Ryan, Donna H., Lingvay, Ildiko, Colhoun, Helen M., Deanfield, John, Emerson, Scott S., Kahn, Steven E., Kushner, Robert F., Marso, Steve, Plutzky, Jorge, Brown-Frandsen, Kirstine et al. · 2020 · American Heart Journal
2. Pharmacotherapy of obesity: available medications and drugs under investigation.
   Pilitsi, Eleni, Farr, Olivia M., Polyzos, Stergios A., Perakakis, Nikolaos, Nolen-Doerr, Eric, Papathanasiou, Aimilia-Eirini, Mantzoros, Christos S. · 2019 · Metabolism
3. GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
   Wang, Jing-Yue, Wang, Quan-Wei, Yang, Xin-Yu, Yang, Wei, Li, Dong-Rui, Jin, Jing-Yu, Zhang, Hui-Cong, Zhang, Xian-Feng · 2023 · Frontiers in Endocrinology
4. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
   Maselli, Daniel B., Camilleri, Michael · 2020 · Advances in Experimental Medicine and Biology
5. Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions
   Sourbh Suren Garg, Kriti Kushwaha, Rupal Dubey, Jeena Gupta · 2023 · Diabetes Research and Clinical Practice
6. Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
   Hjerpsted, Julie B., Flint, Anne, Brooks, Ashley, Axelsen, Mads B., Kvist, Trine, Blundell, John · 2018 · Diabetes, Obesity and Metabolism
7. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
   Hammoud, Rola, Drucker, Daniel J. · 2023 · Nature Reviews Endocrinology
8. Body Weight Considerations in the Management of Type 2 Diabetes
   Caroline Margaret Apovian, Jennifer Okemah, Patrick Mahlen O'Neil · 2018 · Advances in Therapy
9. Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates
   Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A. et al. · 2016 · Diabetes, Obesity and Metabolism
10. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    le Roux, Carel W, Steen, Oren, Lucas, Kathryn J, Startseva, Elena, Unseld, Anna, Hennige, Anita M · 2024 · The Lancet Diabetes &amp; Endocrinology
11. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
    Wharton, Sean, Davies, Melanie, Dicker, Dror, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Pedersen, Sue D. · 2022 · Postgraduate Medicine
12. Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee
    Amanda Ruth Vest, Michael C. Y. Chan, Anita M Deswal, Michael M. Givertz, Carolyn L. Lekavich, Terry A. Lennie, Sheldon E. Litwin, Lauren Parsly, Jo E. Rodgers, Michael W. Rich et al. · 2019 · Journal of Cardiac Failure
13. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
    Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi · 2016 · Cell Metabolism
14. Semaglutide for the treatment of obesity
    Chao, Ariana M., Tronieri, Jena S., Amaro, Anastassia, Wadden, Thomas A. · 2023 · Trends in Cardiovascular Medicine
15. HIV and antiretroviral therapy-related fat alterations
    John Robert Koethe, Claire Lagathu, Jordan E. Lake, Peré Domingo, Alexandra Calmy, Julian Falutz, Todd Tarquin Brown, Jacqueline Capeau · 2020 · Nature Reviews Disease Primers
16. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
    Halawi, Houssam, Khemani, Disha, Eckert, Deborah, O'Neill, Jessica, Kadouh, Hoda, Grothe, Karen, Clark, Matthew M, Burton, Duane D, Vella, Adrian, Acosta, Andres et al. · 2017 · The Lancet Gastroenterology &amp; Hepatology
17. Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
    Emily E. Brown, John P.H. Wilding, Thomas M. Barber, Uazman Alam, Daniel James Cuthbertson · 2019 · Obesity Reviews
18. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
    Jensterle, Mojca, Rizzo, Manfredi, Haluzík, Martin, Janež, Andrej · 2022 · Advances in Therapy
19. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
    Pantelis A. Sarafidis, Charles Joseph Ferro, Enrique Morales, Alberto Ortíz, Jolanta Małyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, José Manuel Valdivielso, Denis P. Fouque et al. · 2019 · Nephrology Dialysis Transplantation
20. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis.
    Han, Sabrina H, Safeek, Rachel, Ockerman, Kyle, Trieu, Nhan, Mars, Patricia, Klenke, Audrey, Furnas, Heather, Sorice-Virk, Sarah · 2023 · Aesthetic Surgery Journal
21. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
    Frias, Juan Pablo, Nauck, Michael A., Van, Joanna, Benson, Charles, Bray, Ross, Cui, Xuewei, Milicevic, Zvonko, Urva, Shweta, Haupt, Axel, Robins, Deborah A. · 2020 · Diabetes, Obesity and Metabolism
22. Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer <scp>GLP</scp> ‐ <scp>1RA</scp> ‐based weight‐loss therapies
    Thomsen, Reimar W., Mailhac, Aurélie, Løhde, Julie B., Pottegård, Anton · 2025 · Diabetes Obesity and Metabolism
23. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
    Jensen, Simon Birk Kjær, Blond, Martin Bæk, Sandsdal, Rasmus Michael, Olsen, Lisa Møller, Juhl, Christian Rimer, Lundgren, Julie Rehné, Janus, Charlotte, Stallknecht, Bente Merete, Holst, Jens Juul, Madsbad, Sten et al. · 2024 · eClinicalMedicine
24. Western diets and chronic diseases
    Timon Erik Adolph, Herbert Tilg · 2024 · Nature Medicine
25. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
    Neeland, Ian J, Marso, Steven P, Ayers, Colby R, Lewis, Bienka, Oslica, Robert, Francis, Wynona, Rodder, Susan, Pandey, Ambarish, Joshi, Parag H · 2021 · The Lancet Diabetes &amp; Endocrinology
26. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
    Wadden, Thomas A., Tronieri, Jena Shaw, Sugimoto, Danny, Lund, Michael Taulo, Auerbach, Pernille, Jensen, Camilla, Rubino, Domenica · 2020 · Obesity
27. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
    Wharton, Sean, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Goldman, Bryan, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Thomsen, Mette, Wadden, Thomas A. et al. · 2022 · Diabetes, Obesity and Metabolism
28. Anti-obesity therapy: from rainbow pills to polyagonists
    Müller, T.D., Clemmensen, C., Finan, B., DiMarchi, R.D., Tschöp, M.H. · 2018 · Pharmacological Reviews
29. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
    Sandsdal, Rasmus M., Juhl, Christian R., Jensen, Simon B. K., Lundgren, Julie R., Janus, Charlotte, Blond, Martin B., Rosenkilde, Mads, Bogh, Adrian F., Gliemann, Lasse, Jensen, Jens-Erik B. et al. · 2023 · Cardiovascular Diabetology
30. Untitled work
    Knowler · 2011 · 10.1001/archinternmed.2011.367
31. A fully automated conversational artificial intelligence for weight loss: longitudinal observational study among overweight and obese adults
    Stein, Natalie, Brooks, Kevin · 2017 · JMIR Diabetes
32. Central nervous system regulation of eating: Insights from human brain imaging
    Olivia M. Farr, Chiang‐Shan R. Li, Christos Socrates Mantzoros · 2016 · Metabolism
33. White Paper AGA: POWER — Practice Guide on Obesity and Weight Management, Education, and Resources
    Andres J Acosta, Sarah Elizabeth Streett, Mathew Kroh, Lawrence Jay Cheskin, Katherine H. Saunders, Marina S. Kurian, Marsha Schofield, Sarah E. Barlow, Louis J. Aronne · 2017 · Clinical Gastroenterology and Hepatology
34. Pharmacotherapy of type 2 diabetes: An update
    Jagriti Upadhyay, Stergios A. Pοlyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula Α. Paschou, Niki Katsiki, PATRICIA C. UNDERWOOD, Kyung‐Hee Park, Jochen Seufert, Eun Seok Kang et al. · 2017 · Metabolism
35. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
    Young Jin Tak, Sang Yeoup Lee · 2020 · The World Journal of Men s Health
36. Obesity in South and Southeast Asia—A new consensus on care and management
    Tham, Kwang Wei, Abdul Ghani, Rohana, Cua, Sioksoan C., Deerochanawong, Chaicharn, Fojas, Mia, Hocking, Samantha, Lee, June, Nam, Tran Quang, Pathan, Faruque, Saboo, Banshi et al. · 2023 · Obesity Reviews
37. Obesity and Dyslipidemia
    Barbora Nussbaumerová, Hana Rosolová · 2023 · Current Atherosclerosis Reports
38. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study
    Elkind-Hirsch, Karen E., Chappell, Neil, Shaler, Donna, Storment, John, Bellanger, Drake · 2022 · Fertility and Sterility
39. Probiotic Mixture of Lactobacillus plantarum Strains Improves Lipid Metabolism and Gut Microbiota Structure in High Fat Diet-Fed Mice
    Huizhen Li, Fei Liu, Jingjing Lu, Jialu Shi, Jiaqi Guan, Fenfen Yan, Bailiang Li, Guicheng Huo · 2020 · Frontiers in Microbiology
40. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis
    Cai, Xiaoling, Yang, Wenjia, Gao, Xueying, Chen, Yifei, Zhou, Lingli, Zhang, Simin, Han, Xueyao, Ji, Linong · 2018 · Obesity
41. Reappraisal of GIP Pharmacology for Metabolic Diseases
    Finan, Brian, Müller, Timo D., Clemmensen, Christoffer, Perez-Tilve, Diego, DiMarchi, Richard D., Tschöp, Matthias H. · 2016 · Trends in Molecular Medicine
42. The pathogenesis of obesity
    Oussaada, Sabrina M., van Galen, Katy A., Cooiman, Mellody I., Kleinendorst, Lotte, Hazebroek, Eric J., van Haelst, Mieke M., ter Horst, Kasper W., Serlie, Mireille J. · 2019 · Metabolism
43. Diets and drugs for weight loss and health in obesity – An update
    Jan Aaseth, Stian Ellefsen, Urban Alehagen, Tine Mejlbo Sundfør, Jan Alexander · 2021 · Biomedicine & Pharmacotherapy
44. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials
    Iqbal, Junaid, Wu, Hui‐Xuan, Hu, Nan, Zhou, Ying‐Hui, Li, Long, Xiao, Fen, Wang, Ting, Jiang, Hong‐Li, Xu, Shi‐Na, Huang, Bi‐Ling et al. · 2022 · Obesity Reviews
45. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial
    Mok, Jessica, Adeleke, Mariam O., Brown, Adrian, Magee, Cormac G., Firman, Chloe, Makahamadze, Christwishes, Jassil, Friedrich C., Marvasti, Parastou, Carnemolla, Alisia, Devalia, Kalpana et al. · 2023 · JAMA Surgery
46. Probiotic with or without Fiber Controls Body Fat Mass, Associated with Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial
    Stenman, Lotta K., Lehtinen, Markus J., Meland, Nils, Christensen, Jeffrey E., Yeung, Nicolas, Saarinen, Markku T., Courtney, Michael, Burcelin, Rémy, Lähdeaho, Marja-Leena, Linros, Jüri et al. · 2016 · EBioMedicine
47. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
    McGowan, Barbara M, Bruun, Jens M, Capehorn, Matt, Pedersen, Sue D, Pietiläinen, Kirsi H, Muniraju, Hanna Angelene Kudiyanur, Quiroga, Maria, Varbo, Anette, Lau, David C W · 2024 · The Lancet Diabetes &amp; Endocrinology
48. Weight regain after cessation of medication for weight management: systematic review and meta-analysis
    West, Sam, Scragg, Jadine, Aveyard, Paul, Oke, Jason L, Willis, Lia, Haffner, Stella J P, Knight, Heather, Wang, Danni, Morrow, Sarah, Heath, Laura et al. · 2026 · BMJ
49. Issues in Measuring and Interpreting Human Appetite (Satiety/Satiation) and Its Contribution to Obesity
    Catherine Gibbons, Mark Hopkins, Kristine Beaulieu, Pauline Oustric, John Edward Blundell · 2019 · Current Obesity Reports
50. Obesity and diabetes
    Chrysoula Boutari, Antea J. DeMarsilis, Christos Socrates Mantzoros · 2023 · Diabetes Research and Clinical Practice
51. FDA-Approved Anti-Obesity Drugs in the United States
    Homayoun L. Daneschvar, Mark D. Aronson, Gerald W. Smetana · 2016 · The American Journal of Medicine
52. Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
    Andrew J. Krentz, Ken Fujioka, Marcus Hompesch · 2016 · Diabetes Obesity and Metabolism
53. Addressing obesity in aging patients
    Batsis, John A., Zagaria, Alexandra B. · 2018 · Medical Clinics of North America
54. Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review
    Victoria Salem, Noara Khaled Alhusseini, Habeeb Ibrahim Abdul Razack, Anastasia Naoum, Omar T. Sims, Saleh A. Alqahtani · 2022 · Obesity Reviews
55. Obesity Pharmacotherapy
    Katherine H. Saunders, Devika Umashanker, Leon I. Igel, Rekha B. Kumar, Louis J. Aronne · 2017 · Medical Clinics of North America
56. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
    Chandani Patel Chavez, Kenneth J. Cusi, Sushma Kadiyala · 2021 · The Journal of Clinical Endocrinology & Metabolism
57. Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity
    Kyoung Kon Kim, Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Jung Hwan Park, Sang Youl Rhee, Eon Ju Jeon, Eungu Kang, Ga Eun Nam, Hye Yeon Koo et al. · 2023 · Journal of Obesity & Metabolic Syndrome
58. INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Galina Afanas'evna Mel'nichenko, Natalya Valentinovna Mazurina, Elena Nikolaevna Andreeva, I. Z. Bondarenko, Гусова Залина Руслановна, F. K. Dzgoeva, М. С. Елисеев, Ekaterina Vladimirovna Ershova et al. · 2021 · Obesity and metabolism
59. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
    Jensen, Anders Boisen, Renström, Frida, Aczél, Stefan, Folie, Patrick, Biraima-Steinemann, Magdalena, Beuschlein, Felix, Bilz, Stefan · 2023 · Obesity Surgery
60. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options
    Arturo Cesaro, Gianantonio De Michele, Fabio Fimiani, Vincenzo Acerbo, Gianmaria Scherillo, Giovanni Signore, Francesco Paolo Rotolo, Francesco Scialla, Giuseppe Raucci, Domenico Panico et al. · 2023 · Frontiers in Cardiovascular Medicine
61. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons
    Adams, Jessica M., Pei, Hongjuan, Sandoval, Darleen A., Seeley, Randy J., Chang, Rui B., Liberles, Stephen D., Olson, David P. · 2018 · Diabetes
62. New insights into the treatment of obesity
    Blüher, Matthias, Aras, Mohini, Aronne, Louis J., Batterham, Rachel L., Giorgino, Francesco, Ji, Linong, Pietiläinen, Kirsi H., Schnell, Oliver, Tonchevska, Elena, Wilding, John P.H. · 2023 · Diabetes, Obesity and Metabolism
63. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
    Jastreboff, Ania M., Kushner, Robert F. · 2023 · Annual Review of Medicine
64. Reversal of liver fibrosis: From fiction to reality
    Miguel Eugenio Zoubek, Christian Trautwein, Pavel Strnad · 2017 · Best Practice & Research Clinical Gastroenterology
65. Non-alcoholic Fatty Liver Disease: A Clinical Update
    Joseph M Pappachan, S. Vinod Babu, Babu Krishnan, Nishal Ravindran · 2017 · Journal of Clinical and Translational Hepatology
66. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
    Simon Kloock, Christian G. Ziegler, Ulrich Dischinger · 2023 · Pharmacology & Therapeutics
67. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist
    Iepsen, Eva W., Zhang, Jinyi, Thomsen, Henrik S., Hansen, Elizaveta L., Hollensted, Mette, Madsbad, Sten, Hansen, Torben, Holst, Jens J., Holm, Jens-Christian, Torekov, Signe S. · 2018 · Cell Metabolism
68. Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding
    Alcantara, Ivan C., Tapia, Ana Pamela Miranda, Aponte, Yeka, Krashes, Michael J. · 2022 · Nature Metabolism
69. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment
    Trapp, Stefan, Brierley, Daniel I. · 2022 · British Journal of Pharmacology
70. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
    Mozaffarian, Dariush, Agarwal, Monica, Aggarwal, Monica, Alexander, Lydia, Apovian, Caroline M, Bindlish, Shagun, Bonnet, Jonathan, Butsch, W Scott, Christensen, Sandra, Gianos, Eugenia et al. · 2025 · The American Journal of Clinical Nutrition
71. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
    Locatelli, João Carlos, Costa, Juliene Gonçalves, Haynes, Andrew, Naylor, Louise H., Fegan, P. Gerry, Yeap, Bu B., Green, Daniel J. · 2024 · Diabetes Care
72. Centrally Acting Agents for Obesity: Past, Present, and Future
    Coulter, Ann A., Rebello, Candida J., Greenway, Frank L. · 2018 · Drugs
73. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
    Moiz, Areesha, Filion, Kristian B., Toutounchi, Helia, Tsoukas, Michael A., Yu, Oriana H.Y., Peters, Tricia M., Eisenberg, Mark J. · 2025 · Annals of Internal Medicine
74. From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
    Jens Juul Holst · 2019 · Frontiers in Endocrinology
75. Liraglutide: A New Option for the Treatment of Obesity
    Wesley A. Nuffer, Jennifer M. Trujillo · 2015 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
76. Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes
    Bray, George A., Ryan, Donna H. · 2021 · Diabetes, Obesity and Metabolism
77. Current and future therapies for type 1 diabetes
    Bernt Johan von Scholten, Frederik Flindt Kreiner, Stephen C. L. Gough, Matthias von Herrath · 2021 · Diabetologia
78. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
    Jang Won Son, Sungrae Kim · 2020 · Diabetes & Metabolism Journal
79. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
    Tan, Qiming, Akindehin, Seun E., Orsso, Camila E., Waldner, Richelle C., DiMarchi, Richard D., Müller, Timo D., Haqq, Andrea M. · 2022 · Frontiers in Endocrinology
80. Defined Paraventricular Hypothalamic Populations Exhibit Differential Responses to Food Contingent on Caloric State
    Chia Li, Jovana S. Navarrete, Jing Liang-Guallpa, Chunxia Lü, Samuel C Funderburk, Rui B. Chang, Stephen D. Liberles, David P. Olson, Michael J. Krashes · 2018 · Cell Metabolism
81. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
    Wharton, Sean, Kuk, Jennifer L., Luszczynski, Magdalena, Kamran, Elham, Christensen, Rebecca A. G. · 2019 · Clinical Obesity
82. Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review
    Suresh Subramaniam, William A. Fletcher · 2016 · Journal of Neuro-Ophthalmology
83. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
    María Isabel Del Olmo-García, Juan Francisco Merino-Torres · 2018 · Journal of Diabetes Research
84. Nutritional priorities to support <scp>GLP</scp> ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
    Mozaffarian, Dariush, Agarwal, Monica, Aggarwal, Monica, Alexander, Lydia, Apovian, Caroline M., Bindlish, Shagun, Bonnet, Jonathan, Butsch, W. Scott, Christensen, Sandra, Gianos, Eugenia et al. · 2025 · Obesity
85. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy
    Kornelius, Edy, Huang, Jing-Yang, Lo, Shih-Chang, Huang, Chien-Ning, Yang, Yi-Sun · 2024 · Scientific Reports
86. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum
    William T. Cefalu, John B. Buse, Jaakko O. Tuomilehto, G. Alexander Fleming, Ele Ferrannini, Hertzel C. Gerstein, Peter H. Bennett, Ambady Ramachandran, Itamar Raz, Julio Rosenstock et al. · 2016 · Diabetes Care
87. From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
    Nikolaos Theodorakis, Maria Nikolaou · 2025 · Biomolecules
88. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
    Stefanakis, Konstantinos, Kokkorakis, Michail, Mantzoros, Christos S. · 2024 · Metabolism
89. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update
    Nadolsky, Karl, Garvey, W. Timothy, Agarwal, Monica, Bonnecaze, Alex, Burguera, Bartolome, Chaplin, Michelle DeGeeter, Griebeler, Marcio L., Harris, Samantha R., Schellinger, Jeffrey N., Simonetti, Juliana et al. · 2025 · Endocrine Practice
90. Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
    Alkhezi, Omar S., Alahmed, Abdullah A., Alfayez, Osamah M., Alzuman, Osama A., Almutairi, Abdulaali R., Almohammed, Omar A. · 2023 · Obesity Reviews
91. Long-Term Weight Loss Strategies for Obesity
    Kheniser, Karim, Saxon, David R, Kashyap, Sangeeta R · 2021 · The Journal of Clinical Endocrinology &amp; Metabolism
92. Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy
    Robert F. Kushner · 2018 · Progress in Cardiovascular Diseases
93. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Blüher, Matthias, Rosenstock, Julio, Hoefler, Josef, Manuel, Raymond, Hennige, Anita M. · 2024 · Diabetologia
94. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
    Sinha, Rachel, Papamargaritis, Dimitris, Sargeant, Jack A., Davies, Melanie J. · 2023 · Journal of Obesity &amp; Metabolic Syndrome
95. Derivatization with fatty acids in peptide and protein drug discovery
    Peter Kurtzhals, Søren Østergaard, Erica Nishimura, Thomas Kjeldsen · 2022 · Nature Reviews Drug Discovery
96. Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial
    Maselli, Daniel, Atieh, Jessica, Clark, Matthew M., Eckert, Deborah, Taylor, Ann, Carlson, Paula, Burton, Duane D., Busciglio, Irene, Harmsen, W. Scott, Vella, Adrian et al. · 2022 · Obesity
97. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
    Khoo, Joan, Hsiang, John C., Taneja, Ranu, Koo, Seok‐Hwee, Soon, Gaik‐Hong, Kam, Carmen J., Law, Ngai‐Moh, Ang, Tiing‐Leong · 2019 · Liver International
98. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort
    Hongyi Zhu, Lenian Zhou, Qiuke Wang, Qianying Cai, Fan Yang, Hanqiang Jin, Yiwei Chen, Yanyan Song, Changqing Zhang · 2023 · Annals of the Rheumatic Diseases
99. Drug Therapies for Diabetes
    Roni Weinberg Sibony, Omri Segev, Saar Dor, Itamar Raz · 2023 · International Journal of Molecular Sciences
100. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years
     Thomas Danne, Torben Biester, Kerstin Kapitzke, Sanja Hald Jacobsen, Lisbeth Vestergård Jacobsen, Kristin C. Carlsson Petri, Paula M. Hale, Olga Kordonouri · 2016 · The Journal of Pediatrics